Published On : October 2026
Buyers new to this category often begin with a product comparison, but surgeons and procurement teams who have purchased before tend to begin one step earlier, with the surgical approach.
The approach decides which devices are even eligible, because a microcatheter designed for access from inside the eye is specified differently from one designed for access through an external incision, and a hospital that performs only one approach has no use for the other.
The overall picture of the glaucoma surgical microcatheter market shows how these specification choices add up across the eight segmentation dimensions, and this page focuses on the first three of them, which are product type, technology platform and surgical approach.
Product type describes the device itself, and the report tracks four categories: illuminated canaloplasty microcatheters, non-illuminated surgical microcatheters, integrated drug delivery microcatheters and next-generation navigation-enhanced microcatheters.
Technology platform describes the system a microcatheter belongs to, and the report separates traditional canaloplasty systems, MIGS-oriented canaloplasty platforms and image-guided systems.
Surgical approach describes how the eye is entered, and the report separates the ab-interno approach from the ab-externo approach.
These three dimensions interact rather than stack, since a given approach is usually delivered on a particular platform and the platform in turn constrains which product types can be used with it.
A hospital standardising on one platform therefore narrows its product choices considerably, and a manufacturer that supplies several product types on one platform has a different relationship with that hospital than a manufacturer supplying a single device that must be adapted to the hospital's existing system.
Because the surgeon usually leads this decision, the specification conversation tends to start in the operating theatre and reach the purchasing office only after the approach, platform and product type have been settled by clinical preference.
This page describes device categories and purchasing logic only, and it makes no statement about the clinical performance of any product, platform or approach.
|
BUYER INSIGHT A purchasing team that asks which approach the surgeons intend to use before it asks which product to buy will usually shorten the evaluation, because the approach removes whole product categories from consideration at the outset. |
The first product type split in the report is between illuminated canaloplasty microcatheters and non-illuminated surgical microcatheters, and the distinction is one of device construction rather than of procedure.
An illuminated microcatheter carries a light source along its length, so the position of the tip can be seen from outside the eye while the device is advanced, whereas a non-illuminated microcatheter relies on other means of positioning and does not carry a light source.
From a purchasing point of view the two types differ in what must be bought alongside the catheter, because an illuminated device generally requires a compatible light source and console, while a non-illuminated device is often usable with equipment a surgical facility already owns.
That difference means an illuminated microcatheter is often purchased as part of a system, with the console representing a durable purchase and the catheter itself a recurring consumable, whereas a non-illuminated device behaves more like a conventional surgical consumable ordered in line with case volume.
The report treats illuminated canaloplasty microcatheters as the largest product type category, reflecting their established position in canaloplasty, and treats non-illuminated surgical microcatheters as a smaller category used where facilities prefer simpler equipment requirements.
Buyers weigh several practical factors when choosing between the two, including whether the facility already has a compatible console, how many canaloplasty cases it performs each month, how much training surgeons and nurses will need, and how a purchase fits the capital and consumable budgets held by different departments.
For a high-volume surgery centre, a system purchase can be spread across many cases and the console becomes a small part of the cost per procedure, while for a facility that performs few cases a system purchase can be hard to justify on volume alone and a simpler device may attract more interest.
Manufacturers selling illuminated systems therefore tend to invest in placement arrangements and surgeon training, since console placement is what creates the recurring demand for the catheters that follow it.
None of this implies that one construction is clinically preferable, and the report does not compare the two on outcomes.
The two remaining product type categories are newer, and both extend what a microcatheter does beyond the basic function of creating and maintaining access.
An integrated drug delivery microcatheter is designed so that a substance can be delivered through the device as part of the procedure, which introduces additional regulatory and handling considerations compared with a device that only provides access.
A next-generation navigation-enhanced microcatheter adds features intended to help the surgeon track or guide the device during use, and the report treats it as the fastest-growing product type category from a small base.
Both categories matter to buyers because they change the evaluation checklist, since a device with a drug delivery function brings pharmaceutical-style questions about compatibility and handling into a purchasing conversation that would otherwise concern a surgical consumable only.
Similarly, a navigation-enhanced device raises questions about compatibility with imaging and visualisation equipment, which can bring biomedical engineering and sometimes information technology staff into the decision alongside surgeons and purchasing managers.
The vendor selection criteria in the report apply with particular force to these newer categories, because clinical evidence, regulatory approvals and training support are all named criteria, and a newer device category generally has less accumulated evidence and fewer approvals than an established one.
Regulatory approval is also uneven across regions, so a device that a surgeon in one country can buy freely may not yet be approved in another, and a multi-country hospital group must check the approval position country by country before standardising.
Adoption of these newer categories is expected to be gradual and surgeon-led, with early use concentrated in academic ophthalmology centres and specialist eye hospitals before spreading to ambulatory surgery centres and private clinics.
|
TECHNOLOGY WATCH Newer microcatheter categories widen the group of staff involved in a purchase, since drug handling and imaging compatibility bring pharmacy and biomedical engineering into discussions that were previously held between surgeons and purchasing managers. |
Technology platform is the dimension that most clearly separates long-established canaloplasty practice from the newer minimally invasive approaches, and the report identifies three platform categories.
Traditional canaloplasty systems are built around the established canaloplasty workflow and remain the largest technology platform category, because they have the longest installed base and the widest surgeon familiarity.
MIGS-oriented canaloplasty platforms are designed to fit the faster, less invasive workflows associated with minimally invasive glaucoma surgery, and they form the fastest-growing platform category as more surgeons incorporate glaucoma procedures into cataract surgery.
A buyer comparing these platforms usually also needs to understand the procedure types each technology platform supports, since a platform that suits standalone canaloplasty may be a poor fit for a facility whose volume comes mainly from combined cataract and glaucoma cases.
The practical difference for a hospital is the fit with its existing surgical schedule, because combined procedures are performed in cataract-length operating slots and a platform that adds substantial time or setup to a cataract case is harder to schedule than one designed around that slot.
Training burden differs as well, since a surgeon already experienced in traditional canaloplasty can move across to a related system with modest additional training, while a cataract surgeon entering glaucoma surgery for the first time will need more structured support.
Platform choice is also a long-term commitment for many buyers, because consoles, instruments and trained staff all accumulate around the chosen system, which makes later switching costly and gives incumbent platforms a degree of stickiness.
For manufacturers, this stickiness shapes strategy in both directions, as an established platform benefits from the reluctance of buyers to change, while a new entrant must either demonstrate a clear workflow advantage or position itself alongside existing equipment.
The report separates these platform categories so that buyers and suppliers can see where each is concentrated by region and end user, without implying that either is more effective than the other.
Image-guided systems are the third technology platform category, and they combine a microcatheter with imaging or visualisation capability intended to support positioning during the procedure.
They are the most equipment-intensive of the three platform categories, because the imaging component is a significant capital item and typically needs integration with other operating room equipment.
That integration makes image-guided systems more of an institutional purchase than a surgeon-level one, and the buying committee for such a system commonly includes surgeons, biomedical engineering, finance and, in larger organisations, a capital equipment committee.
Hospitals evaluating this category often look at the manufacturers whose platform breadth differs most, because a supplier able to provide imaging, console and consumables together simplifies a purchase that would otherwise involve several vendors and several contracts.
Image-guided systems also tend to appear first in academic ophthalmology centres and large specialty eye hospitals, where research interest, higher case volumes and capital budgets make adoption easier to justify.
Adoption in ambulatory surgery centres and private clinics is slower, since capital constraints weigh more heavily and the number of eligible cases per site is usually smaller.
Service and support are important buying considerations for this category, as a system dependent on imaging equipment needs reliable maintenance and rapid repair, and buyers often ask where service engineers are located before they commit.
Across regions, image-guided systems are concentrated in advanced surgical markets, where capital budgets and reimbursement for the associated procedures are most established, with more limited uptake in emerging ophthalmology markets.
The two surgical approaches in the report differ in how the eye is entered, and the difference matters for equipment, training and the settings where each approach is performed.
The ab-interno approach reaches the target structure from inside the eye through a small corneal incision, and it accounts for the largest surgical approach category because it fits well with cataract surgery and with minimally invasive workflows.
The ab-externo approach reaches the target structure through an external incision in the eye wall, and it remains in use in traditional canaloplasty practice, particularly among surgeons trained in that technique.
This page deliberately does not describe either approach at a technical level, because the report concerns the market for the devices rather than the conduct of surgery, and nothing here should be read as guidance on technique.
The commercial consequence of the split is that the same hospital may need different device ranges depending on which approach its surgeons use, and a facility with surgeons using both approaches may need to hold two sets of stock.
Training programmes follow the approach, so a manufacturer offering ab-interno systems builds its education around cataract surgeons and MIGS-oriented workflows, while one supporting ab-externo use builds around glaucoma specialists with experience in the established technique.
Purchasing patterns also differ, since ab-interno devices used in combined procedures are often ordered in line with cataract volume, while ab-externo devices are ordered for a smaller number of scheduled standalone glaucoma operations.
Regional preference varies with surgeon training traditions, with the ab-interno approach more prominent in markets where cataract surgery volumes are high and minimally invasive procedures are reimbursed, and the ab-externo approach persisting where established canaloplasty practice is strongest.
Buyers assembling a specification should confirm with their surgeons which approach each theatre will use, because that single answer settles which product types and platforms remain on the shortlist.
The report covers four product types (illuminated canaloplasty, non-illuminated surgical, integrated drug delivery and navigation-enhanced microcatheters), three technology platforms (traditional canaloplasty systems, MIGS-oriented platforms and image-guided systems) and two surgical approaches (ab-interno and ab-externo).
An illuminated microcatheter carries a light source so its tip position can be seen from outside the eye, and it generally needs a compatible console. A non-illuminated microcatheter does not carry a light source and is often usable with equipment a facility already owns.
The approach decides which devices are eligible, since access from inside the eye and access through an external incision call for different specifications, so surgeons and buyers usually settle it first.
MIGS-oriented canaloplasty platforms form the fastest-growing platform category as more surgeons incorporate glaucoma procedures into cataract surgery, while traditional canaloplasty systems remain the largest category by installed base.
They are the most equipment-intensive platform, need integration with operating room equipment and involve capital committees, so they appear first in academic ophthalmology centres and large specialty eye hospitals with higher case volumes and capital budgets.